TIANJIN, China, June 3 /PRNewswire-Asia/ -- Asymchem is pleased to announce its recent award by Pfizer Inc. as the 2008 Top Intermediates CMO Award, and announces the opening of a high potency API and drug product facility, despite the current challenging economic environment. Meanwhile, Dr. Chris Huber joins Asymchem Laboratories Inc. as Director of Chemical Development and is ready to help expand and strengthen Asymchem's already well-established large scale manufacturing services.
I. Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem. May 1, 2009 in Groton, Connecticut
Asymchem Laboratories, Inc., a leading research-based contract manufacturer of APIs, intermediates and Drug Products to the pharmaceutical industry with sites in the U.S. and China, is pleased to announce that Pfizer Inc. recently presented Asymchem with the 2008 Top Intermediates CMO Award.
The award was presented at Pfizer's Groton, Connecticut R&D center on May 1, 2009. The award was the first in an annual series to be presented to high-performing chemical intermediates suppliers. "A global network of high-quality chemical intermediate manufacturers is critical to enable Pfizer to create and sustain a competitive advantage," said Laurie Chipperfield, Director of API Strategic Sourcing.
Ed Kobelski, Global VP Supply Chain at Pfizer, presented the award to Dr. Hao Hong, CEO of Asymchem. "The steady growth of Asymchem's business at Pfizer is the result of their successful execution of each project, ability to achieve R&D speed targets, excellent customer service and high technical proficiency," stated Dr. Kobelski.
Pfizer uses a quantitative/qualitative supplier performance assessment process that combines performance data along with feedback from internal R&D and commercial project managers. Supplier excellence is judged on criteria including supplier value, delivery, account support, and compliance.
"I am very excited and honored to receive this award, and sincerely appreciate Pfizer's recognition of Asymchem's dedicated staff," states Dr. Hao Hong, CEO of Asymchem. "By consistently delivering on time and within spec, we help push through projects that are time critical in the clinical arena. Our new Dunhua cGMP commercial production facility coming online later this year will further expand Asymchem's offerings."
II. Asymchem Announces Opening of High Potency API and Drug Product Facility
May 15, 2009 in TEDA Tianjin, China
Asymchem Laboratories, Inc. is pleased to announce the opening if its high potency Active Pharmaceutical Ingredient (API) and Drug Product facility in TEDA Tianjin, China.
This dedicated facility is located at Asymchem's TEDA Tianjin 1 location, and provides state-of-the art containment for production of potent APIs, as well as tablet and capsule manufacturing that incorporates potent ingredients. The new facility allows Asymchem to operate two separate API manufacturing trains of 50 and 100L, as well as additional facilities for smaller-scale research and production and oral dosage form manufacturing.
"We are pleased to expand our capabilities in process research and manufacturing into the potent compound arena, and provide our partners with cost-effective and quality-driven means for undertaking this type of work in China," states Dr Hao Hong, CEO of Asymchem.
Asymchem seeks to be a leader among Chinese-located manufacturing operations not only in facility design but also worker safety, and the Tianjin potent compound site was designed and validated by recognized and accredited experts in the potent compound community. As one of the largest and most respected pharmaceutical manufactures in China, Asymchem is pleased to extend its broad range of API and drug product capabilities to this exciting and rapidly emerging field of drug research and development.
III. Dr. Chris Huber joins Asymchem Laboratories Inc. as Director of Chemical Development
April 23, 2009 in Morrisville, NC
Asymchem Laboratories, Inc. is also pleased to announce the recent addition of Dr. Chris Huber as Director of Chemical Development.
Dr. Huber brings to the table over 15 years experience in the pharmaceutical industry (early and late stage), developing process technology for API manufacturing of small molecules. Prior to Asymchem, Dr. Huber directed early phase projects for API manufacturing at Achaogen Inc. and Arena Pharmaceuticals. Much of his career was spent at Pfizer and legacy companies in process chemistry, with focus on optimization, characterization and validation of Phase 3 processes in preparation for commercial manufacturing of APIs.
As Director of Chemical Development, Dr. Huber will help expand and strengthen Asymchem's pilot scale-up, tech transfers and production efforts into commercial manufacturing. He will report directly to Dr. Jim Gage, VP of Chemical Development.
"I am very pleased to have Dr. Huber on board to help expand and strengthen Asymchem's already well-established large scale manufacturing services," states Dr Hao Hong, CEO of Asymchem. "With his broad experience in the pharmaceutical industry and proven track record of API manufacturing, I am confident that our commercial capabilities will be further strengthened and solidified."
Dr. Huber received his B.S. and M.S. at the Universitat Regensburg,
Germany under the supervision of Professors Dr. Henri Brunner, Dr. Jurgen
Sauer and Dr. Josef Barthel. He earned his Ph.D. in Organic Chemistry and
Catalysis from the Universitat Regensburg, Germany with Professor Dr. Henri
Brunner. He did his postdoctoral studies at
Asymchem Laboratories Inc. is a leading research-based contract manufacturer specialized in the development and compliant manufacturing (Contract Research and Manufacturing Services) of API's and Drug Products serving the pharmaceutical industry. With a 14-year track record, Asymchem is committed to the highest level of quality and excellence in the integrated CMC services arena. For further information, please visit the Asymchem website at http://www.asymchem.com .
|SOURCE Asymchem Laboratories Inc.|
Copyright©2009 PR Newswire.
All rights reserved